Drugdevelopment
News, views and contacts from the global Drugdevelopment industry
27 April 2017
DAILY UPDATE
Industry News

Capricor reports positive top-line results from Phase I/II trial of CAP-1002 for DMD
US-based biotechnology firm Capricor Therapeutics has reported positive top-line six-month results from the Phase I/II HOPE clinical trial of CAP-1002 to treat duchenne muscular dystrophy (DMD).

ObsEva commences Phase III trials of OBE2109 to treat uterine fibroids
Swiss-based biopharmaceutical firm ObsEva has commenced its Phase III clinical trial programme of OBE2109 to treat uterine fibroids (UF).

SillaJen and Transgene commence enrolment in Europe for Phase III trial of Pexa-Vec
South Korean-based biotherapeutics firm SillaJen and French biotechnology firm Transgene have commenced patient enrolment in Europe for the ongoing Phase III PHOCUS clinical trial of Pexa-Vec to treat advanced liver cancer or hepatocellular carcinoma (HCC).

American Regent begins enrolment in Phase III trial of Injectafer to treat heart failure
Japanese pharmaceutical firm Daiichi Sankyo's division, American Regent, has begun patient enrolment in the Phase III HEART-FID clinical trial of Injectafer (ferric carboxymaltose) for the treatment of heart failure with iron deficiency.

Press Releases

Malvern to Host Webinar on Using Multi-Setection size-exclusion chromatography to Evaluate Biosimilarity
Malvern has announced it will be hosting a new webinar presenting size-exclusion chromatography (SEC) data and discussing the impact of different formulations and external stress conditions on Monoclonal antibodies and biosimilar molecules.

Malvern to Host New Webinar on Difference Between Rheometers and Viscometers
Malvern has announced it will host a new webinar discussing the difference between rheometers and viscometer to help viewers decide which of the two is most suitable for their application.

Pharmatest to Host Seven Presentations at AACR in Washington, US
Pharmatest Services has announced it will attend the annual meeting of American Association for Cancer Research (AACR) in Washington, US.

Shin-Etsu Purchase Gamlen D Series for Formulation Studies
Provider of a wide range of cellulose ether excipients Shin-Etsu PFMD has purchased a Gamlen D series powder compaction analyser for a laboratory application in Wiesbaden, Germany.

Malvern March Webinars
Malvern is hosting two webinars this month: Differential scanning calorimetry (robust and powerful physical characterisation of therapeutic protein products) and Cement (composition, structure, and fineness - we are stronger together!).

White Papers

Determining Characterisations of Biopharmaceutical Stability with DSC
An important parameter in production, manufacturing, formulation, and long-term storage, protein stability has large effects on biopharmaceutical products and higher stability means for...

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture
Systag Systems presents ePAT, a cost-effective device for automation in the laboratory....

Benefits of Trehalose
Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of...

Gamlen Study: Breaking Anisotropic Rod-Shaped Particles
Gamlen presents a study conducted by V. Penkavova1, L. Kulaviak1, M.C. Ruzicka1, M. Puncochar, and P. Zamostny on the 'Beaking of Anisotropic Rod-Saped...

Reasons to Upgrade to a MicroCal PEAQ-DSC System
Differential Scanning Calorimetry (DSC) is a tool for protein stability characterisation in drug development. Its data is used to advance stable and developable proteins into the pipeline,...

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.